Low Neutralizing Antibody Responses Against SARS-CoV-2 in Elderly Myeloma Patients After the First BNT162b2 Vaccine Dose

Research letter reports study (n=44; age 59 to 92 yrs; 104 controls) showing 1st dose of BNT162b2 leads to lower levels of neutralising antibodies against SARS-CoV-2 in this population compared to non-myeloma controls of similar age and gender (20.6% vs. 32.5% at day 22; p<0.01)

Source:

Blood